Triptolide Inhibits Epileptic Seizures by Rescuing the Neuroinflammation-Related GABAergic Dysfunction in Mice

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Epilepsy is a neurological disorder characterized by recurrent seizures.
• Triptolide (TPL), derived from Tripterygium wilfordii Hook F (TWHF), possesses potent anti-inflammatory and immunosuppressive properties.
• The potential antiepileptic effects of TPL, particularly its impact on neuroinflammation, warrant investigation.

Purpose of the Study:

• To evaluate the antiepileptic effect of triptolide (TPL).
• To investigate the disease-modifying effects of TPL in various epilepsy models.
• To explore the mechanism underlying TPL's antiepileptic action, focusing on GABAergic inhibition and neuroinflammation.

Main Methods:

• Utilized pentylenetetrazol (PTZ), maximal electroshock seizure (MES), corneal (6 Hz) kindling, and kainic acid (KA) mouse models.
• Employed EEG recording, behavioral tests, and extracellular recording with optogenetics to assess antiepileptic and disease-modifying effects.
• Investigated the role of IL-1β and the NF-κB pathway in TPL's mechanism of action.

Main Results:

• TPL (50 μg/kg) did not show direct anticonvulsive effects but retarded kindling acquisition and reduced seizure severity.
• TPL (10 or 50 μg/kg) demonstrated disease-modifying effects in the KA-induced temporal lobe epilepsy (TLE) model.
• TPL enhanced hippocampal GABAergic inhibition, reduced hippocampal IL-1β levels, and IL-1β was found to attenuate GABAergic function.

Conclusions:

• Low-dose TPL may exert antiepileptic effects by ameliorating hippocampal GABAergic neural circuit dysfunction.
• The mechanism involves mitigating neuroinflammation, specifically by targeting IL-1β.
• TPL shows promise for treating epilepsy by addressing underlying neuroinflammatory processes.